Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach.
Crit Rev Oncol Hematol
; 199: 104247, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38307393
ABSTRACT
BACKGROUND:
Immunotherapy represented a turning point for treating extensive small-cell lung cancer (ES-SCLC). Although, many issues remain debated.METHODS:
A group of Italian medical and radiation oncologists with expertise in managing patients with ES-SCLC developed a list of statements divided in six areas of interest. The Delphi method was used to assess the consensus on the defined list of statements.RESULTS:
32 statements were included in the final list to be voted by the Delphi panel, and 26 reached a consensus on the agreement. A prompt involvement of a multidisciplinary team is a priority to provide an integrated treatment strategy. First-line recommended treatment is immunotherapy in combination with platinum-based chemotherapy and etoposide for four cycles followed by maintenance immunotherapy.CONCLUSIONS:
While awaiting new data from clinical trials and real-world studies, these recommendations can represent a useful tool to guide the management of ES-SCLC patients in daily practice.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Delphi Technique
/
Consensus
/
Small Cell Lung Carcinoma
/
Immunotherapy
/
Lung Neoplasms
Type of study:
Guideline
Limits:
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Crit Rev Oncol Hematol
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
Year:
2024
Type:
Article